Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesOrthopedics/MusculoskeletalVentura County Superion Spacer Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy 060

    Superion Interspinous Spacer for Spinal Stenosis Medical Policy

    Customize your policy alerts

    Sign up for venturacountyhealthcareplan Policy 060 alerts

    Get alerted when Policy 060 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of Superion interspinous spacer implantation for skeletally mature patients with symptomatic, moderate lumbar spinal stenosis and neurogenic claudication. Coverage requires specified clinical findings, failed conservative treatment, appropriate surgical candidacy, and absence of listed contraindications.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicySuperion Interspinous Spacer for Spinal Stenosis
    Policy CodePolicy 060
    Change TypeNo material change
    Effective DateNov 14, 2019
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionDocument at least 6 months of qualifying nonoperative treatment before requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    50+Minimum age for the stated indication

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 months
    Required duration of nonoperative treatment
    1-2 levelsPermitted lumbar treatment levels
    >25%Reduction defining moderate stenosis
    BMI >40Morbid obesity contraindication
    4 CPT + 1 HCPCSBilling codes identified by the policy

    Covered Indication and Contraindications

    Covered Indication

    Covered when all of the following clinical criteria are met:

    Covered indication

    • Patient and disease characteristics: Skeletally mature patient age 50 or older with moderately severe intermittent neurogenic claudication secondary to clinically and radiographically confirmed lumbar spinal stenosisAge ≥50; moderate stenosis defined as >25% reduction of the anteroposterior dimension

      Moderate stenosis must include nerve root crowding compared with the adjacent normal level and may be degenerative, with or without Grade 1 spondylolisthesis.

    • Treatment levels: Implantation is planned at one or two adjacent lumbar levels from L1 through L51 or 2 adjacent levels; no more than 2 levels
    • Failed nonoperative care: The patient has undergone at least 6 months of nonoperative treatment consisting of NSAIDs and at least one of rest, restricted activities of daily living, physical therapy, or steroid injections≥6 months
    • Cause and surgical candidacy: The vascular cause of claudication is absent or is considered a minimal contributor to symptoms, and the provider judges the patient to be a poor candidate for more invasive or extensive surgery

      Examples include a bad reaction to general anesthesia, morbid obesity with severe symptoms after failure of a weight-reduction program, an unusual airway, or unique anatomy.

    Contraindications

    Not covered when any of the following contraindications is present:

    • Anatomic or structural contraindication: Spinal anatomy or disease would prevent proper implant placement or cause the device to be unstable after implantation; degenerative or isthmic spondylolisthesis of Grade 2 or higher; degenerative or other scoliosis with a Cobb angle greater than 25 degrees; bony fracture or metastasis; ankylosed segment at the affected level; significant lumbar instability; or prior fusion, decompression, or other surgery in the area of concernGrade ≥2; Cobb angle >25°; sagittal-plane translation >4.0 mm or 15%; local sagittal-plane rotation >15% at L1-2, L2-3, or L3-4, or >20% at L4-5
    • Clinical contraindication: Cauda equina syndrome; severe osteoporosis; active systemic infection or infection localized to the implantation site; axial back pain only without leg, buttock, or groin pain; or back or leg pain of unknown etiology

      Cauda equina syndrome is neural compression causing neurogenic bladder or bowel dysfunction. Severe osteoporosis is bone mineral density more than 2.5 standard deviations below the adult normal mean in the spine or hip.

    Coverage is excluded when spinal anatomy or disease would prevent proper implant placement or make the device unstable after implantation. Contraindications include Grade 2 or higher spondylolisthesis, scoliosis with a Cobb angle greater than 25 degrees, bony fracture or metastasis, an ankylosed affected segment, or prior fusion, decompression, or other surgery at the treatment site.

    Additional exclusions include significant lumbar instability on standing flexion-extension radiographs, cauda equina syndrome, severe osteoporosis, active systemic or implantation-site infection, axial back pain without leg, buttock, or groin pain, pain of unknown etiology, and BMI greater than 40 kg/m2. Coverage is also excluded after failure of a prior FDA-approved interspinous spacer, when fusion or laminectomy is otherwise contraindicated, or when the patient has a titanium or titanium-alloy allergy.

    Billing Codes and Key Thresholds

    Covered CPT CodesCPTCovered
    22867placement without fusion, with open decompression, including image guidance; single level
    22868second level
    22869placement without open decompression or fusion, including image guidance; single level
    22870second level
    Covered HCPCS CodeHCPCSCovered
    C1821Interspinous process distraction device (implantable)
    Minimum Age
    Minimum age50 years or older
    Patient statusSkeletally mature
    Indication contextModerately severe intermittent neurogenic claudication secondary to clinically and radiographically confirmed lumbar spinal stenosis
    Nonoperative Treatment Duration
    Minimum durationAt least 6 months
    Medication requirementNonoperative treatment must include NSAIDs
    Additional treatment

    Documentation and Coverage Risk

    Documentation Required

    Complete Clinical Criteria and Contraindication Review

    Before requesting coverage, the provider must document that the patient meets the policy's clinical indication for the Superion interspinous spacer and has been evaluated for every listed contraindication or exclusion. The device is limited to skeletally mature patients with qualifying lumbar spinal stenosis and may be implanted at one or two adjacent levels from L1 through L5.

    • Confirm all indication criteria, imaging findings, treatment history, and level limitations.
    • Document the review of spinal anatomy, comorbidities, prior procedures, instability, infection, bone quality, and other contraindications.
    Prior Authorization

    Required Clinical Review Before Submission

    Coverage is at risk when the record does not establish the required indication and exclusion review. The provider should submit a complete clinical assessment rather than relying solely on a diagnosis code or procedure request.

    Procedure Overview

    An interspinous spacer is implanted between adjacent vertebral spinous processes and expanded to distract the neural foramina. This mechanism helps decompress the nerves and adjacent structures by maintaining increased space in the affected segment. The Superion Interspinous Spacer is intended for skeletally mature patients with symptomatic moderate degenerative lumbar spinal stenosis, with or without Grade 1 spondylolisthesis, after conservative treatment has failed. It may be implanted at one or two adjacent lumbar levels from L1 through L5.

    Clinical Definitions

    Neurogenic Claudication
    SymptomsLeg, buttock, or groin pain
    Provoking factorsPosition or extension and/or moderate activity
    Relieving factorsFlexion and/or rest
    Moderate Symptoms
    Sitting functionAble to sit with minimal discomfort for 50 minutes without pain
    Walking functionAble to walk 50 feet or more
    Clinical meaningThese findings define moderate symptoms
    Policy Summary
    PayerVentura County Health Care Plan
    PolicySuperion Interspinous Spacer for Spinal Stenosis
    Policy CodePolicy 060
    Change TypeNo material change
    Effective DateNov 14, 2019
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionDocument at least 6 months of qualifying nonoperative treatment before requesting coverage.
    SourceLink
    On This Page
    Covered Indication and ContraindicationsBilling Codes and Key ThresholdsDocumentation and Coverage RiskProcedure OverviewClinical Definitions
    Other contraindication:
    Body mass index greater than 40 kg/m²; failure of a prior FDA-approved interspinous spacer; fusion or laminectomy is otherwise contraindicated; or allergy to titanium or titanium alloy
    BMI >40 kg/m²
    At least one of rest, restricted activities of daily living, physical therapy, or steroid injections
    Moderate Stenosis
    Dimensional thresholdMore than 25% reduction of the anteroposterior dimension
    Comparison levelCompared with the next adjacent normal level
    Assessment methodDetermined by CT scanning or MRI
    Moderate Functional Definition
    Sitting thresholdAble to sit with minimal discomfort for 50 minutes without pain
    Walking thresholdAble to walk 50 feet or more
    DefinitionThese thresholds define moderate symptoms
    Treatment Levels
    Permitted treatment levelsOne or two adjacent lumbar levels
    Spinal rangeLevels from L1 through L5
    Maximum extentNo more than two levels
    Morbid Obesity Contraindication
    BMI thresholdGreater than 40 kg/m2
    ClassificationMorbid obesity
    Coverage statusListed as a contraindication
    • Document the qualifying diagnosis, symptoms, age, stenosis severity, imaging, conservative treatment, vascular assessment, surgical candidacy, and treatment level(s).
    • Address each applicable contraindication and explain why the device can be safely implanted.
    Documentation Required

    Document Symptoms and Clinical Diagnosis

    The patient must be age 50 or older with moderately severe intermittent neurogenic claudication caused by a clinically and radiographically confirmed diagnosis of lumbar spinal stenosis. Document leg, buttock, or groin pain induced by extension or moderate activity and relieved by flexion or rest; moderate symptoms include the ability to sit with minimal discomfort for 50 minutes and walk 50 feet or more.

    • Record the diagnosis of lumbar spinal stenosis and the associated neurogenic claudication symptoms.
    • Do not submit for axial back pain alone, pain without leg/buttock/groin involvement, or pain of unknown etiology.
    • Document that the patient is skeletally mature and age 50 or older.
    Documentation Required

    Confirm Stenosis With Imaging

    The record must provide radiographic confirmation of moderate degenerative lumbar spinal stenosis, with or without Grade 1 spondylolisthesis. Moderate stenosis requires more than a 25% reduction in anteroposterior dimension compared with the next adjacent normal level and nerve-root crowding compared with that level.

    • Submit supporting x-ray, MRI, and/or CT findings.
    • Identify the affected lumbar level(s) and show that the planned treatment is limited to one or two adjacent levels from L1 through L5.
    • For the policy definition of moderate stenosis, document CT or MRI evidence of the required narrowing and nerve-root crowding.

    Unsupported block type: documentation

    Documentation Required

    Address Alternative Causes and Surgical Candidacy

    The provider must establish that vascular claudication is absent or only a minimal contributor to the symptoms and must explain why the patient is a poor candidate for more invasive or extensive surgery. The rationale should be individualized and supported in the clinical record.

    • Document the assessment of vascular causes of claudication and its relationship to the patient's symptoms.
    • Explain relevant factors such as a bad reaction to general anesthesia, morbid obesity after failure of a weight-reduction program when severe symptoms persist, unusual airway, unique anatomy, or another reason for avoiding more invasive surgery.
    Documentation Required

    Screen for Contraindications and Exclusions

    Screen for and document the absence of every listed contraindication before implantation. Any anatomy or condition that could prevent proper placement, cause implant instability, or otherwise fall within the policy exclusions must be addressed in the submission.

    • Spinal anatomy or disease preventing proper implantation or causing post-implant instability; Grade 2 or higher degenerative or isthmic spondylolisthesis; degenerative or other scoliosis with Cobb angle greater than 25 degrees; bony fractures or metastases; and ankylosed segments at the affected level(s).
    • Cauda equina syndrome with neurogenic bladder or bowel dysfunction; severe osteoporosis defined by spine or hip DEXA or equivalent bone mineral density more than 2.5 standard deviations below the adult mean; prior fusion, decompression, or other surgery in the area of concern; and active systemic or localized implantation-site infection.
    • Significant lumbar instability on standing flexion-extension radiographs, defined as sagittal translation greater than 4.0 mm or 15%, or local sagittal-plane rotation greater than 15% at L1-2, L2-3, or L3-4, or greater than 20% at L4-5.
    • Axial back pain only without leg, buttock, or groin pain; back or leg pain of unknown etiology; BMI greater than 40 kg/m²; failure of a prior FDA-approved interspinous spacer; fusion or laminectomy otherwise contraindicated; and allergy to titanium or titanium alloy.
    Denial Risk

    Denial Risk: Core Indication Criteria Not Met

    Failure to document any core indication requirement creates a denial risk. Coverage is vulnerable when the patient is younger than 50, lacks the qualifying diagnosis or symptoms, does not have confirmed moderate stenosis, has not completed the required conservative treatment, has a significant vascular contributor, is not a poor candidate for more invasive surgery, or the requested levels do not meet policy limits.

    • Age must be 50 or older and the patient must be skeletally mature.
    • The record must support moderate degenerative lumbar spinal stenosis with moderately severe intermittent neurogenic claudication and the required clinical and radiographic confirmation.
    • At least six months of NSAIDs plus rest, restricted ADLs, PT, or steroid injections must be documented.
    • The procedure may involve only one or two adjacent lumbar levels, no more than two, from L1 through L5.
    Denial Risk

    Denial Risk: Any Contraindication Present

    The presence of any listed contraindication or exclusion creates a denial risk and may make the procedure noncovered under this policy. The provider should resolve, rule out, or clearly address the condition with objective supporting documentation before seeking authorization.

    • A contraindication includes disqualifying anatomy, instability, spondylolisthesis, scoliosis, fracture or metastasis, ankylosis, cauda equina syndrome, severe osteoporosis, prior surgery at the site, infection, isolated axial pain, unexplained pain, BMI greater than 40 kg/m², prior spacer failure, contraindicated fusion or laminectomy, or titanium allergy.
    • Do not proceed on the assumption that a contraindication is immaterial; document the provider's evaluation and rationale for any potentially applicable exclusion.
    Moderate Spinal Stenosis
    Dimensional reductionMore than 25% reduction of the anteroposterior dimension
    ComparisonCompared with the next adjacent normal level
    Nerve-root findingNerve root crowding compared with the normal level
    Significant Lumbar Instability
    Sagittal-plane translationGreater than 4.0 mm or 15% on standing flexion-extension radiographs
    Rotation at L1-2, L2-3, or L3-4Greater than 15%
    Rotation at L4-5Greater than 20%
    Severe Osteoporosis
    Assessment methodBone mineral density from a DEXA scan or equivalent method
    Assessment sitesSpine or hip
    DefinitionMore than 2.5 standard deviations below the adult normal mean
    Cauda Equina Syndrome
    Underlying findingNeural compression
    Bladder dysfunctionNeurogenic bladder dysfunction
    Bowel dysfunctionNeurogenic bowel dysfunction